Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III ,Randomized,Placebo-Conrolled,Muticenter,Double-Blind Study Comparing JS001 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasophapyngeal Cancer

Trial Profile

Phase III ,Randomized,Placebo-Conrolled,Muticenter,Double-Blind Study Comparing JS001 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasophapyngeal Cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Toripalimab (Primary) ; Cisplatin; Gemcitabine
  • Indications Nasopharyngeal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Shanghai Junshi Biosciences
  • Most Recent Events

    • 07 Mar 2019 Planned End Date changed from 21 Aug 2020 to 21 Aug 2021.
    • 27 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 13 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top